Rare Top-quark Decays to Higgs boson in MSSM

In full one-loop generality and in next-to-leading order in QCD, we study rare top to Higgs boson flavour changing decay processes $t\to q h$ with $q=u,c$ quarks, in the general MSSM with R-parity conservation. Our primary goal is to search for enhanced effects on $Br(t\to q h)$ that could be visible at current and high luminosity LHC running. To this end, we perform an analytical expansion of the amplitude in terms of flavour changing squark mass insertions that treats both cases of hierarchical and degenerate squark masses in a unified way. We identify two enhanced effects allowed by various constraints: one from holomorphic trilinear soft SUSY breaking terms and/or right handed up squark mass insertions and another from non-holomorphic trilinear soft SUSY breaking terms and light Higgs boson masses. Interestingly, even with $\mathcal{O}(1)$ flavour violating effects in the, presently unconstrained, up-squark sector, SUSY effects on $Br(t\to q h)$ come out to be unobservable at LHC mainly due to leading order cancellations between penguin and self energy diagrams and the constraints from charge- and colour-breaking minima (CCB) of the MSSM vacuum. An exception to this conclusion may be effects arising from non-holomorphic soft SUSY breaking terms in the region where the CP-odd Higgs mass is smaller than the top-quark mass but this scenario is disfavoured by recent LHC searches. Our calculations for $t\to q h$ decay are made available in SUSY_FLAVOR numerical library.Comment: 32 pages, 6 figures; version accepted for publication in JHEP: additional comparison with literature added, minor misprints correcte

Topcolor assisted technicolor models and muon anomalous magnetic moment

We discuss and estimate the contributions of the new particles predicted by topcolor assisted technicolor(TC2) models to the muon anomalous magnetic moment $a_{\mu}$. Our results show that the contributions of Pseudo Goldstone bosons are very small which can be safely ignored. The main contributions come from the ETC gauge boson $x_{\mu}$ and topcolor gauge boson $Z^{\prime}$. If we demand that the mass of $Z^{\prime}$ is consistent with other experimental constrains, its contributions are smaller than that of $x_{\mu}$. With reasonable values of the parameters in TC2 models, the observed BNL results for $a_{\mu}$ could be explained.Comment: latex file, 11 pages, several figures and references adde

SmeftFR v3 -- Feynman rules generator for the Standard Model Effective Field Theory

We present version 3 of SmeftFR, a Mathematica package designed to generate the Feynman rules for the Standard Model Effective Field Theory (SMEFT) including the complete set of gauge invariant operators up to dimension-6 and the complete set of bosonic operators of dimension-8. Feynman rules are generated with the use of FeynRules package, directly in the physical (mass eigenstates) basis for all fields. The complete set of interaction vertices can be derived, including all or any chosen subset of SMEFT operators. As an option, the user can also choose preferred gauge fixing, generating Feynman rules in unitary or $R_\xi$-gauges. The novel feature in version-3 of SmeftFR is its ability to calculate SMEFT interactions consistently up to dimension-8 in EFT expansion (including quadratic dimension-6 terms) and express the vertices directly in terms of user-defined set of input-parameters. The derived Lagrangian in the mass basis can be exported in various formats supported by FeynRules, such as UFO, FeynArts etc. Initialisation of numerical values of Wilson coefficients of higher dimension operators is interfaced to WCxf format. The package also includes a dedicated Latex generator allowing to print the result in clear human-readable form. The SmeftFR v3 is publicly available at www.fuw.edu.pl/smeft.Comment: 51 pages, version accepted for publication in Computer Physics Communications. arXiv admin note: substantial text overlap with arXiv:1904.0320

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

BACKGROUND: Routine adjuvant administration of trastuzumab (T) has been implemented in most centers, but its economic impact has not yet been well examined. METHODS: A Markov model was constructed based on clinical data of the Herceptin Adjuvant (HERA) and the Finland Herceptin (FinHer) trials. Costs from the perspective of a Swiss health care provider were calculated based on resource use. RESULTS: On the basis of HERA data, our model yielded an overall survival rate of 71.8% for the T group versus 62.8% for the control group [risk ratio (RR) = 0.87) after 10 years and 62.9% versus 52.7% (RR = 0.84) after 15 years. Cost-effectiveness resulted in 40505 Euros (EUR) per life years gained (LYG) after 10 years and 19673 EUR per LYG after 15 years. For the FinHer regimen, overall survival after 10 and 15 years resulted in 81.8% versus 66.1% (RR = 0.81) and 73.6% versus 57.0% (RR = 0.77). Costs of 8497 EUR per patient could be saved after 10 years and 9256 EUR after 15 years compared with the control group. CONCLUSION: In a long-term perspective, adjuvant T based on the HERA regimen can be considered cost-effective. The regimen used in the FinHer trial is even cost saving, but estimations are based on a single small tria